667. New Antiretroviral Agents
Session: Symposium: HIV State-of-the-Art
Friday, October 19, 2012: 10:30 AM
Room: SDCC 28 ABCDE
Despite the current availability of 26 FDA-approved antiretroviral drugs, we continue to need newer drugs that are more potent, less toxic, more tolerable, more convenient, and/or have improved virologic activity against drug-resistant viral strains. The current antiretroviral agent pipeline is full, with new investigational nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors (EIs), integrase inhibitors (IIs), and other compounds with new mechanisms of action. Investigational agents that have unique properties and those that are the farthest along in clinical development will be reviewed.
Previous Presentation | Next Presentation >>
Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.